Using an optimized, highly sensitive, ddPCR assay, we found that 83% of patients with PIK3CA mutation in the metastatic tumor tissue had detectable circulating PIK3CA mutations in their corresponding serum sample, which underlines that the method is highly useful to obtain information regarding tumor characteristics and might be favored over the invasive and time consuming solid biopsies. Here, PIK3CA is linked to neoplasm.